What's Happening?
Scholar Rock has resubmitted its Biologics License Application (BLA) for apitegromab to the U.S. Food and Drug Administration (FDA) for the treatment of spinal muscular atrophy (SMA) in children and adults. Apitegromab is a muscle-targeted therapy that
has shown significant improvements in motor function during a pivotal Phase 3 clinical trial. The resubmission follows a Complete Response Letter from the FDA in September 2025, which cited issues unrelated to apitegromab itself. Scholar Rock has since worked closely with the FDA and Catalent Indiana, the manufacturing facility involved, to address these concerns. The company anticipates FDA acceptance of the BLA within 30 days and a review period of up to six months, with a potential approval expected by late September 2026.
Why It's Important?
The resubmission of the BLA for apitegromab is a critical step in providing a new treatment option for individuals with SMA, a rare and debilitating neuromuscular disease. If approved, apitegromab would be the first muscle-targeted therapy for SMA, potentially improving the quality of life for patients by enhancing motor function. This development could also position Scholar Rock as a leader in the field of myostatin biology, opening doors for further advancements in treating other neuromuscular diseases. The approval and subsequent commercialization of apitegromab could have significant financial implications for Scholar Rock, boosting its market presence and revenue.
What's Next?
Scholar Rock is preparing for the potential approval and launch of apitegromab in both the U.S. and Europe. The company is also working on strengthening its supply chain by including a second U.S.-based fill-finish facility in the BLA resubmission. This strategic move aims to meet the anticipated demand for apitegromab upon approval. Additionally, the European Medicines Agency is reviewing the Marketing Authorisation Application for apitegromab, with a decision expected mid-2026. Scholar Rock's ongoing collaboration with regulatory bodies and its proactive approach to addressing manufacturing concerns highlight its commitment to bringing this innovative treatment to market.
